T
T

Thyssenkrupp

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Bernstein sees Nel's 'competitive moat' unconvincing, prefers Nucera

BUZZ-Bernstein sees Nel's 'competitive moat' unconvincing, prefers Nucera ** Bernstein initiates German hydrogen firm Thyssenkrupp Nucera NCH2.DE with "outperform," seeing it as a market leader by backlog, set to tap into green hydrogen growth from industry decarbonisation ** "Move over amateurs, the professionals have arrived," it says and cuts No
D
T

Research alert on Thyssenkrupp AG withdrawn

CORRECTED-ADVISORY-Research alert on Thyssenkrupp AG withdrawn Corrects to clarify that Thyssenkrupp Nucera is majority owned by Thyssenkrupp AG, and is not an unrelated company Sept 22 (Reuters) - An alert on Bernstein initiating coverage on Thyssenkrupp AG TKAG.DE is wrong and has been withdrawn. The brokerage initiated coverage on Thyssenkrupp Nucera AG & Co KGaa NCH2.DE , which is majority owned by Thyssenkrupp AG.
T

Brooks MacDonald Group, TUI, Weir Group

EUROPE RESEARCH ROUNDUP- Brooks MacDonald Group, TUI, Weir Group Sept 21 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Brooks MacDonald Group, TUI and Weir Group, on Thursday. HIGHLIGHTS * Brooks MacDonald Group Plc BRK.L : RBC cuts target price to 1,900p from 2,100p * Duell Oyj DUELL.HE : Evli Research cuts to hold from buy * Merck KGaA MRCG.DE : Citigroup raises to buy from neutral * TUI AG TUI1n.DE : Jefferies raises to hold f
A
A
A
A
A
B
B
C
D
E
G
L
L
N
O
O
P
R
R
S
T
T
V
V
W
A
A
E
R

Schott Pharma IPO targets market cap of up to 4.3 bln euros

UPDATE 2-Schott Pharma IPO targets market cap of up to 4.3 bln euros Recasts with market cap, adds background BERLIN/LONDON, Sept 18 (Reuters) - The medical vials division of Schott AG launched its initial public offering on Monday, aiming for a valuation of up to 4.3 billion euros ($4.59 billion), it said in a statement. The German glassmaker is offering a 23% stake in its Schott Pharma business at a price of 24.50 euros to 28.50 euros per share.
T

Thyssenkrupp creates green tech division, launches performance programme

Thyssenkrupp creates green tech division, launches performance programme FRANKFURT, Sept 14 (Reuters) - Thyssenkrupp TKAG.DE on Thursday unveiled plans to bundle its businesses with a green technology angle in one segment and launched a performance programme in a bid to reach its mid-term targets and regain trust among investors. The move is the first major effort by CEO Miguel Lopez , who took over the helm in June, to revive the submarines-to-car parts group's fortunes and languishing share pr
T

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.